Login to Your Account



Other News To Note


Wednesday, March 13, 2013

• Immunubiology Ltd., of Cambridge, UK, said the UK government-backed Biomedical Catalyst awarded the firm about £200,000 (US$300,000) to support preclinical development of pneumococcal vaccine PnuBioVax, which is designed to target a wide range of strains of bacteria.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription